Table 2.
Tumor heterogeneity analysis of central pathology versus mRNA
| Concordance (95 % CI) | Kappa (95 % CI) | Positive agreement | Negative agreement | PPV | NPV | Sample size | |
|---|---|---|---|---|---|---|---|
| ER Hole | 97.0 % (96.1–97.9) | 0.864 (0.825–0.904) | 97.4 (1217/1250) | 94.1 (160/170) | 99.2 (1217/1227) | 82.9 (160/193) | 1420 |
| ER No hole | 97.5 % (97.0–97.9) | 0.880 (0.858–0.903) | 97.7 (3673/3761) | 95.8 (459/479) | 99.5 (3673/3693) | 83.9 (459/547) | 4240 |
| PgR Hole | 87.8 % (86.0–89.4) | 0.666 (0.621–0.710) | 86.5 (996/1151) | 92.9 (250/269) | 98.1 (996/1015) | 61.7 (250/405) | 1420 |
| PgR No hole | 86.8 % (85.7–87.8) | 0.647 (0.621–0.673) | 85.1 (2919/3432) | 94.0 (754/802) | 98.4 (2919/2967) | 59.5 (754/1267) | 4234 |
| HER-2 Hole | 95.8 % (94.8–96.9) | 0.764 (0.706–0.822) | 73.6 (109/148) | 98.4 (1245/1265) | 84.5 (109/129) | 97.0 (1245/1284) | 1413 |
| HER-2 No hole | 96.2 % (95.6–96.8) | 0.756 (0.720–0.792) | 71.8 (280/390) | 98.7 (3775/3826) | 84.6 (280/331) | 97.2 (3775/3885) | 4216 |
Agreement statistics for central pathology assessments versus TargetPrint, for central samples with a biopsy hole and thus assumed to have no tumor heterogeneity in the sample sent for mRNA analysis, and samples without such a hole and thus assumed to be heterogeneous from the mRNA sample